Blueprint Medicines Appoints John Tsai, MD to its Board of Directors | citybiz
John Tsai, MD, Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsaidoctor, to its board of directors. Dr. Tsai, who served as President of Global Drug Development and Chief Medical Officer at Novartis AG from 2018 to 2022, brings to Blueprint Medicines more than 20 years of experience in drug development and …
Blueprint Medicines Appoints John Tsai, MD to its Board of Directors | citybiz Read More »